Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

ICG vs Blue Patent as a Tracer in the Performance of TAD in Patients With cN1 Breast Carcinoma After Neoadjuvant Chemotherapy

NCT06339658 is registered in ClinicalTrials.gov with Hospital Universitari de Bellvitge as lead sponsor.

NCT NCT06339658
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06339658 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
ICG vs Blue Patent as a Tracer in the Performance of TAD in Patients With cN1 Breast Carcinoma After Neoadjuvant Chemotherapy
Lead sponsor
Hospital Universitari de Bellvitge
Phase
Observational
Overall status
Recruiting
Start date
January 1, 2021
Completion date
January 1, 2027
Enrollment
43 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

axillary metastases, breast cancer